Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide.
D000906:Antibodies / Q000032:analysis*; D000937:Antigen-Antibody Reactions; D000941:Antigens; D001379:Azathioprine / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000276:immunology*; D001780:Blood Coagulation Tests; D002850:Chromatography, Gel; D003520:Cyclophosphamide / Q000494:pharmacology*; D004357:Drug Synergism; D005169:Factor VIII / Q000032:analysis / Q000494:pharmacology; D005260:Female; D006406:Hematoma / Q000188:drug therapy; D006470:Hemorrhage / Q000150:complications; D006801:Humans; D007108:Immune Tolerance; D007074:Immunoglobulin G / Q000032:analysis; D007165:Immunosuppression Therapy; D008551:Melena / Q000150:complications; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011233:Precipitin Tests; D011565:Psoriasis / Q000097:blood / Q000150:complications; D012141:Respiratory Tract Infections / Q000150:complications / Q000188:drug therapy; D014221:Triamcinolone / Q000009:adverse effects
D000906:Antibodies; D000941:Antigens; D007074:Immunoglobulin G; D014221:Triamcinolone; D003520:Cyclophosphamide; D005169:Factor VIII; D001379:Azathioprine; D008727:Methotrexate